Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed‐Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020
Journal of the American Heart Association · 2023
DOI: 10.1161/jaha.122.028573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Catherine G Derington und 8 weiteren Autor:innen. Beteiligte Einrichtung: Intermountain Healthcare Department of Population Health Sciences, Spencer Fox Eccles School of Medicine University of Utah Salt Lake City UT USA. Hauptthemen laut MEDLINE: Antihypertensive Agents, Hypertension. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NHLBI NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Background
Fixed‐dose combination (FDC) antihypertensive products improve blood pressure control and adherence among patients with hypertension. It is unknown to what degree commercially available FDC products meet the current hypertension management prescription patterns in the United States. Methods and Results This cross‐sectional analysis of the National Health and Nutrition Examination Surveys 2015 to March 2020 included participants with hypertension taking ≥2 antihypertensive medications (N=2451). After constructing each participant's regimen according to antihypertensive classes used, we estimated the extent to which the 7 class‐level FDC regimens available in the United States as of January 2023 would match the regimens used. Among a weighted population of 34.1 million US adults (mean age, 66.0 years; 52.8% women; 69.1% non‐Hispanic White race and ethnicity), the proportions using 2, 3, 4, and ≥5 antihypertensive classes were 60.6%, 28.2%, 9.1%, and 1.6%, respectively. The 7 FDC regimens were among 189 total regimens used (3.7%). Overall, 52.7% (95% confidence interval [CI], 48.5%‐57.0%, 18.0 million US adults) of the population were taking a regimen that was available as a class equivalent FDC product, and 47.3% (95% CI, 43.0‐51.5%, 16.1 million US adults) were using a regimen not available as a class‐equivalent FDC product.
Conclusions
About half of US adults with hypertension taking ≥2 antihypertensive classes are using a regimen that is not commercially available as a class‐equivalent FDC product as of January 2023. To maximize the potential benefit of FDCs to improve medication adherence (and thus blood pressure control) among patients taking multiple antihypertensive medications, use of FDC‐compatible regimens and improvements in the product landscape are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Intermountain Healthcare Department of Population Health Sciences, Spencer Fox Eccles School of Medicine University of Utah Salt Lake City UT USA.
- Department of Internal Medicine, Spencer Fox Eccles School of Medicine University of Utah Salt Lake City UT USA.
- Department of Preventive Medicine University of Tennessee Health Science Center TN Memphis USA.
- Institute for Health Research, Kaiser Permanente Colorado Aurora CO USA.
ORCID-Profile: Catherine G Derington, Adam P Bress, Jennifer S Herrick, Joshua A Jacobs, Alexander R Zheutlin, Ransmond O Berchie, Molly B Conroy, William C Cushman, Jordan B King
Förderung
- NCATS NIH HHS
- NHLBI NIH HHS
- NIA NIH HHS
- NCRR NIH HHS
Zitieren
APA
Derington, C. G., Bress, A. P., Herrick, J. S., Jacobs, J. A., Zheutlin, A. R., Berchie, R. O., Conroy, M. B., Cushman, W. C., & King, J. B. (2023). Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed‐Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.028573
Vancouver
Derington CG, Bress AP, Herrick JS, Jacobs JA, Zheutlin AR, Berchie RO, et al. Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed‐Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.028573
BibTeX
@article{Derington2023,
author = {Derington, Catherine G and Bress, Adam P and Herrick, Jennifer S and Jacobs, Joshua A and Zheutlin, Alexander R and Berchie, Ransmond O and Conroy, Molly B and Cushman, William C and King, Jordan B},
title = {Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed‐Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020},
journal = {Journal of the American Heart Association},
year = {2023},
doi = {10.1161/jaha.122.028573}
}
EUVIMED